Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Jan;14(1):1-8.
doi: 10.3904/kjim.1999.14.1.1.

T cell subsets in chronic hepatitis B and the effect of prednisolone withdrawal and interferon alpha-2b

E H Im  1 , B S Lee, J K Sung, S O Lee, K T Lee, S M Lee, S H Kim, K S Seo, J H Kim, S G Kim, N J Kim, H Y Lee
Affiliations
Clinical Trial

T cell subsets in chronic hepatitis B and the effect of prednisolone withdrawal and interferon alpha-2b

E H Im et al. Korean J Intern Med. 1999 Jan.

Abstract

Objectives: The evaluations of the pathogenetic roles of cell mediated immunity and of the preventive effect for disease progression with interferon(IFN) treatment in patients with chronic active hepatitis-B(CAH-B) are the objectives of this study.

Methods: Thirty-two patients with CAH-B were treated with interferon alpha-2b(IFN alpha-2b) with prednisolone withdrawal and 30 control patients were treated with conventional hepatotonics for 6 months. Peripheral total T cell fractions and T cell subsets of the patients with CAH-B, treated with IFN alpha-2b with prednisolone withdrawal, were examined 1 month before administration of prednisolone, and compared with 12 normal controls for assessing the potential role of cellular immunity in the development of CAH-B. To estimate the effectiveness of IFN therapy for the patients with CAH-B, levels of various liver function tests, HBsAg, anti-HBs, HBeAg, anti-HBe, HBV DNA, anti-HCV and others were assessed for the treatment group and compared with control patients at pre- and post-treatment period each.

Results: The value of CD4 was significantly lower in patients with CAH-B than normal controls (36.3 +/- 7.7% vs 42.1 +/- 5.7%, p < 0.05) and the value of CD8 was significantly higher in patients with CAH-B than normal controls (30.6 +/- 10.3% vs 24.3 +/- 5.2%, p < 0.05) before prednisolone administration. The patients in responder group (n = 26) had significantly lower CD4 cells compared with normal controls, but non-responders (n = 6) did not have. The levels of liver function test(LFT) in the patients with IFN alpha-2b treatment with prednisolone withdrawal were not different from the control patient group at pretreatment, but significantly lower than control patient group's after treatment, regardless of response to IFN alpha-2b treatment with prednisolone withdrawal.

Conclusions: The cellular immunity of the host may have a potential role in the pathogenesis of chronicity of hepatitis B infection. IFN alpha-2b treatment with prednisolone withdrawal may be regarded as one of the effective treatment modalities for the inhibition of disease progression in patients with CAH-B.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Eggink HF, Houthoff HJ, Huitema S, Gips CH, Poppema S. Cellular and humoral immune reaction in chronic active liver disease, lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis. Clin Exp Immunol. 1982;50:17. - PMC - PubMed
    1. Dudley FJ, Fox RA, Scherlock S. Cellular immunity and hepatitis associated(Australia) antigen liver disease. Lancet. 1972;1:743. - PubMed
    1. Gudat F, Bianchini L, Sonnabend W, Thiel G, Aenishaenslin W, Stadler CA. Pattern of core and surface expression in liver tissue reflects state of immune response in hepatitis. Lab Invest. 1975;32:1. - PubMed
    1. Doherty PC, Zinkernagel RM. A biologic role for the major histocompatibility antigen. Lancet. 1975;1:1405. - PubMed
    1. Howard CT. Treatment of hepatitis B viral infection. In: Juckerman AJ, editor. Viral Hepatitis and Liver Disease. Alan R. Liss, Inc; 1988. p. 817.

Publication types